Nutriband Exercised Warrants for $1.75 Million

The Orlando-based company converted outstanding warrants into equity to fund clinical development.

Updated on Oct. 13, 2026 in Healthcare

Bold flat-color editorial illustration of pharmaceutical vials, evoking institutional precision in pharmaceutical finance and clinical development. — Nutriband Inc. secured $1.75 million in gross proceeds through the conversion of outstanding warrants to advance its clinical pharmaceutical development program. AI Illustration. Upload story photo >

Live Poll

Do you trust small-cap pharmaceutical companies to successfully bring experimental new drug technologies to market?

Nutriband Inc. has exercised 272,671 NTRBW warrants at a strike price of $6.43, generating $1,753,274 in gross proceeds. This action marks the completion of the firm's warrant conversion, leaving no remaining tradeable warrants.

Why it matters

The capital raised will support the clinical development of AVERSA Fentanyl and the company's upcoming submission for FDA marketing approval. This infusion of cash is a critical step as the organization moves its primary pharmaceutical candidate toward potential commercialization.

Nutriband Inc. secured $1,753,274.53 in gross proceeds by exercising 272,671 NTRBW warrants at $6.43 each. The company estimates that its AVERSA Fentanyl product could reach peak annual US sales between $80 million and $200 million.

The players

Nutriband Inc.

An Orlando-based healthcare company focused on the development of transdermal pharmaceutical products.

The details

The Orlando-based healthcare firm executed the conversion of its outstanding NTRBW warrants, which reached their expiration date on September 30, 2026. With this transaction complete, the company has no further tradeable warrants currently in circulation.

September 30, 2026: The NTRBW warrants reached their expiration date.
October 13, 2026: Nutriband announced the exercise of the warrants.

Market Landscape

This capital injection positions Nutriband to meet the rigorous financial demands required by the FDA drug approval process. By clearing its warrant structure, the company aligns its equity base to compete more effectively within the highly regulated transdermal drug market.

While this financial move does not immediately change retail product pricing or availability for patients, it secures the funding needed for the future development of AVERSA Fentanyl. Shareholders should note that the firm has eliminated its remaining tradeable warrants following this exercise.

The takeaway

The company has now successfully converted all of its outstanding NTRBW warrants into equity. This strategic move simplifies the company's capital structure as it focuses on achieving regulatory milestones for its leading pharmaceutical candidate.